RespireRx Pharmaceuticals — Investor Presentation (December 2021)
15 slides from RespireRx Pharmaceuticals's investor presentation, Dec 14, 2021
Slide 1: Life Sciences Investor Virtual Conference
RespireRx Pharmaceuticals Inc (OTCQB: RSET EIEE SCIENCES INVESTOR VIRGUALE CONIFEIMEINCIE December 2021
Slide 2: Cautionary Notes: Forward Looking Statements
CAUTIONARY NOTES WN RespireRx Pharmaceuticals Inc FORWARD LOOKING STATEMENTS, This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, os am
Slide 3: Cautionary Notes (cont'd): Not a Securities Offering
CAUTIONARY NOTES (cont’d) DR RespireRx Pharmaceuticals Inc NOT A SECURITIES OFFERING This presentation is being provided for informational purposes only. This presentation does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other produc
Slide 4: RespireRx: Capital Structure and Market Metrics
RespireRx: Capital Structure and Market Metrics RespireRx Pharmaceuticals Inc As of September 30, 2021 (unless indicated otherwise) Common Stock (rounded) 90,396,000 Common Stock Equivalents of all Options and Warrants Granted 122,918,000 (rounded)* Total 213,314,000 Market Metrics at December 6, 20
Slide 5: Underlying Science: Neurotransmission
Respire erlying Science ®)RespireRx Pharmaceuticals Inc Neurotransmission * Neurons communicate through a process of neurotransmission in which they release chemical neurotransmitters that bind to specific receptors on adjacent neurons. * RespireRx is developing breakthrough drugs to modify neurotra
Slide 6: Different Approaches Create Different Platforms
Different Approaches Create Different Platforms WN RespireRx Pharmaceuticals Inc Directly Acting Agonists/Antagonists Act directly at the neurotransmitter binding site to either stimulate (agonist) or interfere (antagonist) with the neurotransmitter receptor. Cannabinoids, such as A9-THC , are direc
Slide 7: Separate Business Units for Different Platforms
Separate Business Units for Different Platforms GQ Resp pireRx Pharmaceuticals Inc RespireRx Pharmaceuticals. Inc. (OTCQB:RSPI) *EndeavourRx *ResolutionRx Pharmaceutical Cannabinoids Neuromodulators +We are contemplating the reorganization as there are several advantages to separating these platform
Slide 8: Product Candidate Portfolio Summary
Product Candidate Portfolio Summary | ResolutionRx | Pharmaceutical Cannabinoids Dronabinol (49-THC) Treatment of Obstructive Sleep Apnea (OSA) No approved drugs available for OSA Potential multi-billion $ market — estimated 30 million US patients Successful Phase 2B; Phase 3 ready, pending completi
Slide 9: Product Candidate Development Status
RespireRx - Product Candidate Development Status Re spir eRx Pharmaceuticals Inc Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA —— Dronabinol Formulation — EndeavourRx - Neuromodulators AMPAkines CX717 - ADHD ————— €X1739-Spinal Cord jv yi CX1942 -follow-up compound
Slide 10: Intellectual Property
Intellectual Property WN RespireRx | ResolutionRx | Dronabinol (A9-THC) License to issued method-of-use patent in the US, UK and Germany for the use of dronabinol for treating OSA (expires 2025 in U.S.) Pending patents on broad, enabling dosage and modified release formulations with patent life thro
Slide 11: Global Market Opportunities
Global Market Opportunities DN RespireRx | ResolutionRx | Dronabinol (A9-THC) Obstructive Sleep Apnea (OSA): Potential $ multi-billion market with no approved drugs available Estimated 30 million US patients and 28 million in UK and Germany combined New superior formulation offers potential for impr
Slide 12: RespireRx - Organizational Structure
RespireRx - Organizational Structure RespireRx Pharmaceuticals Inc 12
Slide 13: Planned Short-Term Milestones
Planned Short-Term Milestones d) RespireRx Pharmaceuticals Inc | ResolutionRx | | EndeavourRx | Dronabinol (A9-THC) AMPAkines PK studies with new formulation Initiate SCI phase 2A studies Patent filings Patent filings Pre-IND meeting with FDA GABAkines Phase 3 design completion 2 P = Complete pre-cl
Slide 14: Corporate Summary
Corporate Summary ow RespireRx Pharmaceuticals Inc v Highly desirable assets — advancing clinical programs and patent estate v Diverse portfolio of novel products across multiple therapeutic categories and indications v Broad flexibility in identifying unique investment structures v Strategic partne
Slide 15: Contacts
RespireRx Pharmaceuticals Inc (OLCQEIRSE! GOontacts. shimMones; EresidenucEe EO Uches@lesplurconr SSELISRASE Ve Wells, CAO MALGOUS CLES PILE acon CTRL
RespireRx Pharmaceuticals — Investor Presentation (December 2021) on 6ix